Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug
Tarsus is fronting $450 million to acquire Alkeus for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.
Marissa Russo
Aug 6, 2026 10:30am
IHealthScreen gets FDA nod for dx to spot diabetic retinopathy
Jul 10, 2026 8:55am
Ray shines a light on $125M round targeting genetic eye therapy
Apr 21, 2026 10:33am
J&J hands back failed gene therapy to MeiraGTx
Apr 16, 2026 10:17am
Belite brings FDA filing into view with phase 3 Stargardt win
Dec 1, 2025 8:25am
Lilly bags eye-catching gene therapy in $475M deal
Nov 10, 2025 7:00am
